Rochester, New York, July 14, 2026 – Harter Secrest & Emery LLP, a full-service business law firm with offices throughout New York, recently represented Bone Biologics Corporation (Nasdaq: BBLG) a developer of orthobiologic products for spine fusion markets, in an up to $9.0 Million PIPE with a single healthcare-focused institutional investor with $3.0 million in gross proceeds upfront and up to approximately $6.0 million of potential additional gross proceeds upon the exercise in full of warrants in cash
The team advising Bone Biologics included Securities and Capital Markets attorneys Alexander R. McClean, Scott B. Mosley and Jason W. Delmont.
Bone Biologics was founded to pursue regenerative medicine for bone. The Company is undertaking a clinical study in Australia with select strategic partners that builds on the preclinical research of the NELL-1 protein. Bone Biologics is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications.
Harter Secrest & Emery’s Securities and Capital Markets practice advises issuers and underwriters in public and private securities offerings and regularly collaborates with boutique investment banks on sophisticated transactions. Clients range from emerging companies to Fortune 100 corporations. The firm’s securities attorneys regularly advise boards of directors and management teams on SEC compliance, corporate governance, public and private securities offerings, NYSE and Nasdaq listing standards, direct listings, state securities regulation and mergers and acquisitions. The firm’s securities attorneys also advise investment advisers and broker-dealers on compliance with SEC and FINRA regulations.